Refractory Childhood EpilepsyPhase 2/3mADNCT00836836
Modified Atkins Diet in Childhood Epilepsy
A Phase 2/3 study testing Modified Atkins diet in people with Refractory Childhood Epilepsy, run by All India Institute of Medical Sciences at 1 site in India.
Trial summary
Seizures are a frequent cause of morbidity in the pediatric age group. Uncontrolled seizures pose a variety of risks to children, including higher rates of mortality, developmental delay and/or regression, and cognitive impairment. The ketogenic diet is a well known treatment option for refractory epilepsy. Read more about this study
- Who is it for?
- Ages 2 to 14 years
- Conditions the study is for
- Refractory Childhood Epilepsy
- What is being tested?
- Modified Atkins diet
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 96 participants
- Where
- 1 siteIndia
- Study dates
- May 2009to Mar 2011
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 to 14 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Seizures persisting daily or more than 7 per week despite the appropriate use of at least 3 anti-epileptic drugs.
Who cannot join
- Known or suspected inborn error of metabolism
- Clinical suspicion of metabolic disorder as evidenced by 2 or more of the following:
- a history of parental consanguinity
- prior affected siblings
- unexplained vomiting
- intermittent worsening of symptoms
Show all 19Show fewer
- recurrent episodes of lethargy
- altered sensorium, or ataxia
- hepatosplenomegaly on examination
- And/ or 2 or more of the following biochemical abnormalities
- High blood ammonia (>80mmol/L)
- High arterial lactate (>2 mmol/L)
- metabolic acidosis (pH <7.2)
- hypoglycaemia (blood sugar <40 mg/dl)
- abnormal urinary aminoacidogram
- presence of reducing sugars or ketones in urine
- positive results on urine neurometabolic screening tests
- Motivational or psychosocial issues in the family which would preclude compliance
- Systemic illness- chronic hepatic, renal or pulmonary disease
Trial locations and contacts
1 site in 1 country.
India1 site
All India Institute of Medical sciences
New Delhi, National Capital Territory of Delhi, 110029
About this study
Official title: Evaluation Of The Efficacy Of The Modified Atkins Diet In Children With Refractory Epilepsy: A Randomized Controlled Trial.
Seizures are a frequent cause of morbidity in the pediatric age group. Uncontrolled seizures pose a variety of risks to children, including higher rates of mortality, developmental delay and/or regression, and cognitive impairment. The ketogenic diet is a well known treatment option for refractory epilepsy. However it is very restrictive and requires strict weighing of foods. The modified Atkins diet is a dietary therapy for intractable childhood epilepsy that was designed to be a less restrictive alternative to the traditional ketogenic diet. Early studies have demonstrated efficacy and safety.There are no randomized trials evaluating the efficacy of the modified Atkins diet in children with refractory epilepsy. Hence this study has been planned to investigate whether there are clear benefits in terms of seizure control in children with refractory epilepsy who are treated with the modified Atkins diet, versus controls.
Read the detailed description
Several severe catastrophic epilepsies present in childhood, including severe infantile myoclonic epilepsy, Lennox Gastaut syndrome and myoclonic-astatic epilepsy (Doose syndrome). Seizures in these disorders are difficult to control; sometimes only at the expense of multiple and toxic levels of antiepileptic medications.Epilepsy surgery is feasible only in a very small number, also the costs are prohibitively high.
Uncontrolled seizures pose a variety of risks to children, including higher rates of mortality, developmental delay and/or regression, and cognitive impairment. Thus effective treatment to control seizures is fundamental to improving overall outcome in childhood epilepsy. The shortcomings of antiepileptic drug therapy and epilepsy surgery have made the need for alternative treatments.
The ketogenic diet is one of the oldest available treatments for epilepsy. It is a medically supervised high fat, low carbohydrate, and restricted protein diet that maintains a chronic state of ketosis while providing proteins and calories for adequate growth. The ketogenic diet compares favourably with the newer antiepileptic drugs (AED's) which have been developed for the treatment epilepsy in children Studies on the newer antiepileptic drugs such as vigabatrin, lamotrigine, tiagabine and gabapentin indicate that only 3% to 10% of all intractable patients achieve complete relief of seizures with the introduction of these newer drugs. Whereas with the ketogenic diet, 33% of patients with intractable epilepsy have more than 50% reduction in seizures and 15-20% become seizure free.Also, many of the children who are maintained on the diet are able to have their antiepileptic drugs decreased or withdrawn. This leads to improvement in alertness, behaviour and cognition.
The traditional ketogenic diet, with 4:1 ratio of fat: carbohydrate + protein has its drawbacks. It restricts calories and fluids, and requires weighing of foods. Protein is generally restricted to 1 g/kg/day, with the majority of remaining calories in the form of fat. This may lead to hypoproteinemia and growth problems. Hospitalization is generally advocated for diet initiation, both for fasting and non-fasting initiation. Side effects of the diet include kidney stones, constipation, acidosis, diminished growth, weight loss, and hyperlipidemia.
The modified Atkins diet is a nonpharmacologic therapy for intractable childhood epilepsy that was designed to be a less restrictive alternative to the traditional ketogenic diet. This diet is started on an outpatient basis without a fast, allows unlimited protein and fat, and does not restrict calories or fluids. Early studies have demonstrated efficacy and safety.13-20 However these studies have been uncontrolled, and have enrolled small numbers of patients. There are no randomized control trials evaluating the efficacy of the modified Atkins diet in children and adults with refractory epilepsy. Hence this study has been was planned to investigate whether there are clear benefits in terms of seizure control in children with refractory epilepsy who are treated with the modified Atkins diet, versus controls.
Eligible children will be randomized using computer generated random number tables in two groups: the intervention and the control arm. Both groups will undergo a baseline 4-week observation period, during which parents will be asked to maintain a daily seizure activity log; recording seizure type, duration and frequency. In the intervention arm, the children will start the modified Atkins diet after this 4-week baseline period. The control group will receive their normal diet with no dietetic input, and remain on the same on-going antiepileptic medication for the 3 months. Anti-epileptic medications will remain unchanged during the 3 month trial period in both groups, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided.
Children will be reviewed as outpatients at 1, 2 and 3 months. Urinary ketones will be checked at each hospital visit. A 3-day dietary intake chart will be reviewed at each visit to compute calorie and carbohydrate intake, and reinforce compliance. Weight will be checked at each visit.
Seizure frequencies will be recorded daily for the 4-week baseline period and the 3 month study period. At the end of the 3 month study period, the number of seizures in the preceding 28 days will be used to calculate the mean seizure number, which will be expressed as a percentage of the mean baseline number of daily seizures (ie, the number of seizures during the 4 weeks before the child started either the diet or the control phase of the study).No changes will be made to the child's antiepileptic medication during the 4-week baseline or the 3-month study periods, unless medically indicated; e.g. drug side effects, or status epilepticus; in which case standard therapy will be provided.
Tolerability of the diet and its side effects will be evaluated by means of parental interview at each visit: vomiting, lethargy, poor appetite, refusal to feed and constipation. Any other parental concerns or parental reports of side effects will also be noted.
- Conditions
- Refractory Childhood Epilepsy
- Being tested
- Modified Atkins diet
- Keywords
- Childhood epilepsy, ketogenic diet
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Modified Atkins dietOther
Also called Dietary intervention
Modified Atkins Diet administration
- Carbohydrates intake will be restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)
- Fats (e.g. cream, butter, oils, ghee) encouraged.
- Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.
- Clear carbohydrate-fluids not restricted.
- Calcium and multivitamin supplementation will be provided.
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Modified Atkins diet arm-In this arm, the children will start the modified Atkins diet after a 4-week baseline period, during which daily seizure log will be maintained. Anti-epileptic medications will remain unchanged during the 3 month trial period, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided. Receives: Other: Modified Atkins diet |
| 2 | No intervention | No Intervention arm- After the 4-week baseline period, this group will receive their normal diet with no dietetic input, and remain on the same on-going antiepileptic medication for the 3 months. Anti-epileptic medications will remain unchanged during the 3 month trial period, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided. At the end of three months, patients in this arm will be offered the option of the modified Atkins diet treatment. This group will not receive any dietetic input |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reduction in seizure frequency at 3 months in the two groups: the modified Atkins diet group, and the control group.
Measured: 3 months
Secondary outcomes (1)
Tolerability and the adverse effects of the modified Atkins diet.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2009 (estimated)
- Study startMay 2009
- Primary completionJan 2011
- Study completionMar 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Refractory Childhood EpilepsyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 96 participants (estimated)
Sponsor and investigators
- Lead sponsor
- All India Institute of Medical Sciences
- Sponsor type
- University, hospital or other
- Collaborators
- Council of Scientific and Industrial Research, India
- Responsible party
- Principal investigator, Suvasini Sharma, All India Institute of Medical Sciences
- Investigators
- Suvasini Sharma, MD, Principal investigator, All India Institute of Medical SciencesSheffali Gulati, MD, Study director, All India Institute of Medical SciencesAnuja Agarwala, MSc, Study chair, All India Institute of Medical Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00836836
- Sponsor's protocol ID
- ModAtkins
- Acronym
- mAD
- Status last verified
- Jan 2019
- First submitted
- 3 Feb 2009
- Last updated
- 15 Jan 2019
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Martin-McGill KJ, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug-resistant epilepsy. Cochrane Database Syst Rev. 2020 Jun 24;6(6):CD001903. doi: 10.1002/14651858.CD001903.pub5.
PubMed 32588435Sharma S, Sankhyan N, Gulati S, Agarwala A. Use of the modified Atkins diet for treatment of refractory childhood epilepsy: a randomized controlled trial. Epilepsia. 2013 Mar;54(3):481-6. doi: 10.1111/epi.12069. Epub 2013 Jan 7.
PubMed 23294191
Study at a glance
From the registry record, last updated by the sponsor on 15 Jan 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation Of The Efficacy Of The Modified Atkins Diet In Children With Refractory Epilepsy: A Randomized Controlled Trial.
- ClinicalTrials.gov ID
- NCT00836836
- Acronym / sponsor ID
- mAD / ModAtkins
- Conditions
- Refractory Childhood Epilepsy
- Keywords
- Childhood epilepsy, ketogenic diet
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 96 participants (estimated)
- Lead sponsor
- All India Institute of Medical SciencesUniversity, hospital or other
- Collaborators
- Council of Scientific and Industrial Research, India
- Study start
- May 2009
- Primary completion
- Jan 2011 (actual)
- Study completion
- Mar 2011 (actual)
- First posted
- 4 Feb 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Seizures are a frequent cause of morbidity in the pediatric age group. Uncontrolled seizures pose a variety of risks to children, including higher rates of mortality, developmental delay and/or regression, and cognitive impairment. The ketogenic diet is a well known treatment option for refractory epilepsy. However it is very restrictive and requires strict weighing of foods. The modified Atkins diet is a dietary therapy for intractable childhood epilepsy that was designed to be a less restrictive alternative to the traditional ketogenic diet. Early studies have demonstrated efficacy and safety.There are no randomized trials evaluating the efficacy of the modified Atkins diet in children with refractory epilepsy. Hence this study has been planned to investigate whether there are clear benefits in terms of seizure control in children with refractory epilepsy who are treated with the modified Atkins diet, versus controls.
Detailed description
Several severe catastrophic epilepsies present in childhood, including severe infantile myoclonic epilepsy, Lennox Gastaut syndrome and myoclonic-astatic epilepsy (Doose syndrome). Seizures in these disorders are difficult to control; sometimes only at the expense of multiple and toxic levels of antiepileptic medications.Epilepsy surgery is feasible only in a very small number, also the costs are prohibitively high.
Uncontrolled seizures pose a variety of risks to children, including higher rates of mortality, developmental delay and/or regression, and cognitive impairment. Thus effective treatment to control seizures is fundamental to improving overall outcome in childhood epilepsy. The shortcomings of antiepileptic drug therapy and epilepsy surgery have made the need for alternative treatments.
The ketogenic diet is one of the oldest available treatments for epilepsy. It is a medically supervised high fat, low carbohydrate, and restricted protein diet that maintains a chronic state of ketosis while providing proteins and calories for adequate growth. The ketogenic diet compares favourably with the newer antiepileptic drugs (AED's) which have been developed for the treatment epilepsy in children Studies on the newer antiepileptic drugs such as vigabatrin, lamotrigine, tiagabine and gabapentin indicate that only 3% to 10% of all intractable patients achieve complete relief of seizures with the introduction of these newer drugs. Whereas with the ketogenic diet, 33% of patients with intractable epilepsy have more than 50% reduction in seizures and 15-20% become seizure free.Also, many of the children who are maintained on the diet are able to have their antiepileptic drugs decreased or withdrawn. This leads to improvement in alertness, behaviour and cognition.
The traditional ketogenic diet, with 4:1 ratio of fat: carbohydrate + protein has its drawbacks. It restricts calories and fluids, and requires weighing of foods. Protein is generally restricted to 1 g/kg/day, with the majority of remaining calories in the form of fat. This may lead to hypoproteinemia and growth problems. Hospitalization is generally advocated for diet initiation, both for fasting and non-fasting initiation. Side effects of the diet include kidney stones, constipation, acidosis, diminished growth, weight loss, and hyperlipidemia.
The modified Atkins diet is a nonpharmacologic therapy for intractable childhood epilepsy that was designed to be a less restrictive alternative to the traditional ketogenic diet. This diet is started on an outpatient basis without a fast, allows unlimited protein and fat, and does not restrict calories or fluids. Early studies have demonstrated efficacy and safety.13-20 However these studies have been uncontrolled, and have enrolled small numbers of patients. There are no randomized control trials evaluating the efficacy of the modified Atkins diet in children and adults with refractory epilepsy. Hence this study has been was planned to investigate whether there are clear benefits in terms of seizure control in children with refractory epilepsy who are treated with the modified Atkins diet, versus controls.
Eligible children will be randomized using computer generated random number tables in two groups: the intervention and the control arm. Both groups will undergo a baseline 4-week observation period, during which parents will be asked to maintain a daily seizure activity log; recording seizure type, duration and frequency. In the intervention arm, the children will start the modified Atkins diet after this 4-week baseline period. The control group will receive their normal diet with no dietetic input, and remain on the same on-going antiepileptic medication for the 3 months. Anti-epileptic medications will remain unchanged during the 3 month trial period in both groups, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided.
Children will be reviewed as outpatients at 1, 2 and 3 months. Urinary ketones will be checked at each hospital visit. A 3-day dietary intake chart will be reviewed at each visit to compute calorie and carbohydrate intake, and reinforce compliance. Weight will be checked at each visit.
Seizure frequencies will be recorded daily for the 4-week baseline period and the 3 month study period. At the end of the 3 month study period, the number of seizures in the preceding 28 days will be used to calculate the mean seizure number, which will be expressed as a percentage of the mean baseline number of daily seizures (ie, the number of seizures during the 4 weeks before the child started either the diet or the control phase of the study).No changes will be made to the child's antiepileptic medication during the 4-week baseline or the 3-month study periods, unless medically indicated; e.g. drug side effects, or status epilepticus; in which case standard therapy will be provided.
Tolerability of the diet and its side effects will be evaluated by means of parental interview at each visit: vomiting, lethargy, poor appetite, refusal to feed and constipation. Any other parental concerns or parental reports of side effects will also be noted.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Other: Modified Atkins dietModified Atkins diet arm-In this arm, the children will start the modified Atkins diet after a 4-week baseline period, during which daily seizure log will be maintained. Anti-epileptic medications will remain unchanged during the 3 month trial period, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided. |
| 2 | No intervention | –No Intervention arm- After the 4-week baseline period, this group will receive their normal diet with no dietetic input, and remain on the same on-going antiepileptic medication for the 3 months. Anti-epileptic medications will remain unchanged during the 3 month trial period, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided. At the end of three months, patients in this arm will be offered the option of the modified Atkins diet treatment. This group will not receive any dietetic input |
Who may qualify
- Ages
- 2 to 14 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- Seizures persisting daily or more than 7 per week despite the appropriate use of at least 3 anti-epileptic drugs.
Key exclusion criteria (19 listed)
- Known or suspected inborn error of metabolism
- Clinical suspicion of metabolic disorder as evidenced by 2 or more of the following:
- And/ or 2 or more of the following biochemical abnormalities
- Motivational or psychosocial issues in the family which would preclude compliance
- Systemic illness- chronic hepatic, renal or pulmonary disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Modified Atkins dietAlso: Dietary interventionModified Atkins Diet administration 1. Carbohydrates intake will be restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.) 2. Fats (e.g. cream, butter, oils, ghee) encouraged. 3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted. 4. Clear carbohydrate-fluids not restricted. 5. Calcium and multivitamin supplementation will be provided. | Other | 1 |
Primary outcome
Reduction in seizure frequency at 3 months in the two groups: the modified Atkins diet group, and the control group.
Time frame: 3 months
1 secondary outcome
Tolerability and the adverse effects of the modified Atkins diet.
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jan 2019.
- Derived from this study: PubMed 32588435Martin-McGill KJ, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug-resistant epilepsy. Cochrane Database Syst Rev. 2020 Jun 24;6(6):CD001903. doi: 10.1002/14651858.CD001903.pub5.
- Derived from this study: PubMed 23294191Sharma S, Sankhyan N, Gulati S, Agarwala A. Use of the modified Atkins diet for treatment of refractory childhood epilepsy: a randomized controlled trial. Epilepsia. 2013 Mar;54(3):481-6. doi: 10.1111/epi.12069. Epub 2013 Jan 7.
Related trials for Refractory Childhood Epilepsy
RecruitingObservational study
Surgery as a Treatment for Medically Intractable Epilepsy
Epilepsy, Epilepsy, Temporal Lobe
Active, not recruitingPhase 2
A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
Pediatric Epileptic Syndrome, Partial-onset Seizures
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Suvasini Sharma, MD principal investigator
All India Institute of Medical Sciences
Sheffali Gulati, MD study director
All India Institute of Medical Sciences
Anuja Agarwala, MSc study chair
All India Institute of Medical Sciences
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Modified Atkins diet in people with Refractory Childhood Epilepsy, run by All India Institute of Medical Sciences at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reduction in seizure frequency at 3 months in the two groups: the modified Atkins diet group, and the control group. (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00836836, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2019.